ABPA allergy IL-12 plethysmography SP-D, 19
adenovirus, 212
adhesion molecules, 140, 183
adjuvant, 393
administration rote, 386
AIDS, 271
alleles, 489
allogeneic MLC cytokines dendritic cells OX 40 T cells, 85
alpha-1 antitrypsin, 489
antibodies antigens, 101
antibodies, 300, 541
antibody deficiency, 325
anti-CTLA-4, 196
anti-DNA, 541
anti-endothelial cell antibodies (AECA), 233, 352
antigen presentation, 107
antigen-experienced T-cells, 431
antigen-presenting-cell, 363
antigens, 37
antinucleosomes, 541
anti-ribosomal, 541
antiviral antibody, 386
apoptosis, 140, 307, 379, 459
arthritis, 150
asthma, interleukin-4, 93
autoantibodies, 224, 233
autoimmune polyendocrine syndrome type II, 131
autoimmunity, 212, 379
β7-integrin, 183
β-chemokines, 286
B cells, 4
bacterial infection, 501
bacterial pneumonia, 271
Bacteroides fragilis, 59
BCG, 190
bovine TB, 190
bovine tuberculosis, 37
bronchiectasis, 325, 489
butyrate, 245
C5a receptor, 43
Campylobacter jejuni, 101
cancer risk, 495
capsular polysaccharide, 467
caseins, 49
CCR5 receptor, 286
CD4+ T cells, 121
CD8, 115
CD27, 424
CD70, 424
CD83, 501
CD138, 370
CD154, 224
cell adhesion molecules, 256
cell differentiation, 441
cell proliferation, 12
cell subpopulations, 263
cellular activation, 67
cellular affinity, 370
cellular immunity, 115
cellular proliferation, 431
chemokine, 314
chemokines, 59, 279
children, 319
Chlamydia pneumoniae, 393
chronic hepatitis B, 107
chronic hepatitis C, 518
collagen-PVP, 140
common variable immunodeficiency, 489, 495
complement, 43, 459
co-stimulation, 75, 224
Crohn's disease, 331
cross-reactivity, 49
CRP, 256
CT scan, 121
CTB-insulin, 204
CTLA-4, 431
CXCR3, 548
cytokine, 32, 67, 212, 263, 449
cytotoxic T-lymphocyte, 424, 509
Δ32 CCR5 deletion, 286
deficiency, 489
dendritic cells, 107, 245, 441
diabetes, 204
diagnosis, 37
docosahexaenoic acid, 12
drug-discovery, 363
ELISA, 49
endothelium, 256
endotoxaemia, 25
eotaxin, 314
epidemiology, 495
epithelial cells, 59, 449
etanercept, 484
extrathymic, 162
Fas, 307
FasL, 307
FcγR, 300
FcγRIIa, 271
F-glycoprotein, 386
fibroblasts, 338
flow cytometry, 263
FOXP3, 127
GAD-65, 131
gangliosides, 441
gene therapy, 212
glomerulonephritis, 43
gluten-sensitive enteropathy, 526
goblet cells, 526
gp-340/DMBT1, 449
granulocytes, 150
GVHD, 162
HAART, 121
Haemophilus influenzae vaccine, 271
Haemophilus influenzae, 325
Helicobactor pylori gastritis, 183
Henoch-Schönlein purpura, 352
HIDS, 484
highly active antiretroviral therapy, 286
HIV, 121, 279
HIV infection, 271
HIV progression, 115
HIV-1, 509
human immunodeficiency virus-1, 286
human, 300, 307
IκB, 59
idiotypes, 233
IFN-γ, 431
IgA deficiency, 495
IgE secreting cells, 370
IL-5, 475
IL-6, 467
IL-7, 431
IL-10, 393
IL-12, 196
imiquimod, 363
immune responses defects, 319
immunoblotting, 49
immunohistochemistry, 404
immunomodulation, 75, 363
immunopathology, 359
immunosuppression, 245
induced sputum, 331
inflammation, 212, 256
iNOS, 150
interferon-α, 279
interferon-γ, 37, 190
interferon, 393
interleukin-10, 241
interleukin-12, 107
interleukin-18, 345
interleukin-18 receptor, 345
intrahepatic lymphocytes, 518
IPEX, 127
Kawasaki disease, 233
Knockout mice, 379
L-[2H5]phenylalanine, 263
linear epitopes, 131
liver histological lesions, 518
long-term, 509
LPS, 25
lung, 359
lupus, 224
lymphocyte migration mucosal addressin cell adhesion molecule-1 (MAdCAM-1), 183
lymphocyte, 12
macrophages, 245
mass spectrometry, 263
matrix technology, 370
memory, 4
mesangial cell, 459
mesangial, 241
mevalonate kinase, 484
MHC class II, 501
mice, 459
MMP-9, 331
monoclonal antibody, 93
monocytes, 245, 256
monocytes/macrophages, 67
mucosa, 359
mucosal immunology, 404
multidrug resistance protein 1, 32
Mycobacteria, 190
naïve T-cells, 431
nasal tolerance, 204
natural T cells, 518
NF-κB, 59
NFAT AP-1, 475
Nijmegen breakage syndrome, 319
nitric oxide, 150, 345
NK type T cells, 162
NOD mice, 204
non-progressor, 509
nucleolus, 532
opportunistic infection, 271
oral, 196
osteoprotegerin, 338
paragonimiasis, 314
PDGF, 241
perforin, 424
periodontitis, 338
peripheral blood mononuclear cells, 345
peripheral blood, 370
Peyer's patches, 404
phage peptide-display libraries, 131
phagocytes, 300
phagocytosis, 271
plasma cell, 370
Plasmodium falciparum, 300
pleural effusion, 314
PMN, 501
pneumococcal polysaccharides, 4
pneumococcal vaccine, 271
potassium ion channels, 67
preclinical safety, 93
proinflammatory cytokines, 140
proliferation, 241
pulmonary, 548
RANKL, 338
RD1 region, 37
recombinant vaccinia, 386
relatives, 495
renal tubule, 43
repopulation, 121
respiratory syncytial virus, 359
rheumatoid arthritis, 140, 156
risk factor, 162
RSV, 386
S and Z, 489
saliva, 101
Sarcoidosis, 331
sepsis, 25
septic shock, 25
serum, 101
skin test, 190
SLE, 541
small intestine, 404
snoRNP, 532
soluble CD163, 156
soybean, 49
SP-D, 449
splenic marginal zone, 4
stem cell source, 162
STI-571, 241
stiff-man syndrome, 131
Streptococcus pneumoniae, 325, 467
systemic autoimmune disease, 532
systemic inflammatory response syndrome, 25
systemic lupus erythematosus, 345
T cell help, 509
T cell maturation, 509
T cell, 338, 363, 475
T lymphocyte, 75, 127, 379
TARC, 314
Tc1 cells, 548
T-cell independent type 2 antigens, 4
T-cell stimulation, 431
TCR, 115
TFFs, 449
Th/To autoantigen, 532
thalidomide, 75
Thymus volume, 121
TIMP1, 331
TIMP-3, 156
TNF, 75
TNF superfamily, 279
TNF-α, 224, 352, 467, 501
TNFRSF1A, 484
tolerance, 196
toll like receptors, 363
toxicology, 93
TRAPS, 484
trefoil peptides, 526
tuberculosis, 32
tucaresol, 363
tumour immunology, 441
type 1 immune response, 548
type 2 immune response, 548
Vα24, 518
vaccination, 359
vaccine, 393
vascular damage, 548
vasculitis, 233, 501
viral persistence, 107
virus, 386
visceral leishmaniasis, 307
vitamin A deficiency, 404
X-chromosome inactivation, 127